Our group previously demonstrated that miR-26a regulates EV secretion from the bone-metastatic prostate cancer cell line PC3M by targeting SHC adaptor protein 4 (SHC4), Prefoldin subunit 4 (PFDN4), and Cysteine and histidine-rich domain (CHORDC)1, and that this suppression attenuates tumor growth, supported by in vitro and in vivo models [107]. The gene discussed is PFDN4; the disease is prostate cancer.